SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it has been added to the Russell 2000(R) Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes in June 2007. The annual reconstitution of the Russell 2000 captures the 2,000 largest U.S. stocks at the end of May, ranking them by total market capitalization.
Russell indexes are widely used by investment managers and institutional investors for both index funds and as benchmarks for passive and active investment strategies.
“We are pleased with our inclusion in the Russell 2000 Index, which reflects our continued positive momentum,” said David Hung, M.D., president and chief executive officer of Medivation. “Russell is an industry leader for stock indexes, and we expect our inclusion will generate greater visibility for our stock among institutional investors.”
About Medivation
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs - Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company’s product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company’s financial and operating results.
Medivation, Inc.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470 ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation, Inc.
Web site: http://www.medivation.com//
